Literature DB >> 1854882

Interleukin-6 in clinical medicine.

J Bauer1, F Herrmann.   

Abstract

This article covers the basic biological functions of interleukin-6 (IL-6) in man. Three major topics are addressed more closely: the involvement of IL-6 in various disease states, particularly those of hematopoietic origin; the diagnostic usefulness of IL-6 measurements in biological fluids; the possible use of IL-6, IL-6 antagonists or IL-6 derivatives as therapeutic means.

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1854882     DOI： 10.1007/bf01729833

Source DB:  PubMed          Journal:  Ann Hematol        ISSN： 0939-5555            Impact factor:   3.673


  106 in total

1.  Combination of interleukins 3 and 6 preserves stem cell function in culture and enhances retrovirus-mediated gene transfer into hematopoietic stem cells.

Authors:  D M Bodine; S Karlsson; A W Nienhuis
Journal:  Proc Natl Acad Sci U S A       Date:  1989-11       Impact factor: 11.205

2.  Transforming growth factor beta downregulates interleukin-1 (IL-1)-induced IL-6 production by human monocytes.

Authors:  T Musso; I Espinoza-Delgado; K Pulkki; G L Gusella; D L Longo; L Varesio
Journal:  Blood       Date:  1990-12-15       Impact factor: 22.113

Review 3.  Biology of multifunctional cytokines: IL 6 and related molecules (IL 1 and TNF).

Authors:  S Akira; T Hirano; T Taga; T Kishimoto
Journal:  FASEB J       Date:  1990-08       Impact factor: 5.191

4.  Interleukin-6 is produced by epidermal cells and plays an important role in the activation of human T-lymphocytes and natural killer cells.

Authors:  T A Luger; T Schwarz; J Krutmann; R Kirnbauer; P Neuner; A Köck; A Urbanski; W Borth; E Schauer
Journal:  Ann N Y Acad Sci       Date:  1989       Impact factor: 5.691

5.  Interleukin-6 is a potent myeloma-cell growth factor in patients with aggressive multiple myeloma.

Authors:  X G Zhang; B Klein; R Bataille
Journal:  Blood       Date:  1989-07       Impact factor: 22.113

6.  Thrombopoietic activity of human interleukin-6.

Authors:  T Nagasawa; T Orita; J Matsushita; M Tsuchiya; T Neichi; I Imazeki; N Imai; N Ochi; H Kanma; T Abe
Journal:  FEBS Lett       Date:  1990-01-29       Impact factor: 4.124

7.  Effect of glucocorticoids on the biologic activities of myeloma cells: inhibition of interleukin-1 beta osteoclast activating factor-induced bone resorption.

Authors:  H Ishikawa; H Tanaka; K Iwato; O Tanabe; H Asaoku; M Nobuyoshi; I Yamamoto; M Kawano; A Kuramoto
Journal:  Blood       Date:  1990-02-01       Impact factor: 22.113

8.  Synergism between interleukin-6 and interleukin-3 in supporting proliferation of human hematopoietic stem cells: comparison with interleukin-1 alpha.

Authors:  A G Leary; K Ikebuchi; Y Hirai; G G Wong; Y C Yang; S C Clark; M Ogawa
Journal:  Blood       Date:  1988-06       Impact factor: 22.113

9.  Accessory function of interleukin-1 and interleukin-6: preferential costimulation of T4 positive lymphocytes.

Authors:  G Tosato; J Miller; G Marti; S E Pike
Journal:  Blood       Date:  1990-02-15       Impact factor: 22.113

10.  Antitumor activity of recombinant interleukin 6 in mice.

Authors:  J J Mulé; J K McIntosh; D M Jablons; S A Rosenberg
Journal:  J Exp Med       Date:  1990-03-01       Impact factor: 14.307
View more
  24 in total

1.  Interleukin-6 is necessary, but not sufficient, for induction of the humanC-reactive protein gene in vivo.

Authors:  B Weinhold; A Bader; V Poli; U Rüther
Journal:  Biochem J       Date:  1997-08-01       Impact factor: 3.857

2.  High interleukin-6 plasma levels in acute promyelocytic leukemia.

Authors:  R Stasi; A Venditti; G del Poeta; M Tribalto; U Coppetelli; G Zaccari; G Papa
Journal:  Ann Hematol       Date:  1992-06       Impact factor: 3.673

3.  Effects of environmentally-relevant levels of perfluorooctane sulfonate on clinical parameters and immunological functions in B6C3F1 mice.

Authors:  Patricia A Fair; Erin Driscoll; Meagan A M Mollenhauer; Sarah G Bradshaw; Se Hun Yun; Kurunthachalam Kannan; Gregory D Bossart; Deborah E Keil; Margie M Peden-Adams
Journal:  J Immunotoxicol       Date:  2011-01-24       Impact factor: 3.000

4.  Selection of hammerhead ribozymes for optimum cleavage of interleukin 6 mRNA.

Authors:  C Hendrix; J Anné; B Joris; A Van Aerschot; P Herdewijn
Journal:  Biochem J       Date:  1996-03-01       Impact factor: 3.857

Review 5.  Multiple myeloma: increasing evidence for a multistep transformation process.

Authors:  M Hallek; P L Bergsagel; K C Anderson
Journal:  Blood       Date:  1998-01-01       Impact factor: 22.113

6.  Maintenance of the nutritional prognostic index predicts survival in patients with unresectable metastatic colorectal cancer.

Authors:  Tetsuro Ikeya; Masatsune Shibutani; Kiyoshi Maeda; Kenji Sugano; Hisashi Nagahara; Hiroshi Ohtani; Kosei Hirakawa
Journal:  J Cancer Res Clin Oncol       Date:  2014-08-15       Impact factor: 4.553

7.  Potential role of interleukin 6 in reactive thrombocytosis and acute phase response in pulmonary tuberculosis.

Authors:  E Unsal; S Aksaray; D Köksal; T Sipit
Journal:  Postgrad Med J       Date:  2005-09       Impact factor: 2.401

8.  Hepatocellular hyperplasia, plasmacytoma formation, and extramedullary hematopoiesis in interleukin (IL)-6/soluble IL-6 receptor double-transgenic mice.

Authors:  P Schirmacher; M Peters; G Ciliberto; M Blessing; J Lotz; K H Meyer zum Büschenfelde; S Rose-John
Journal:  Am J Pathol       Date:  1998-08       Impact factor: 4.307

Review 9.  Interleukin-6 in autoimmune disease. Role of IL-6 in physiology and pathology of the immune defense.

Authors:  L Graeve; M Baumann; P C Heinrich
Journal:  Clin Investig       Date:  1993-08

10.  Differential expression of tumor necrosis factor and interleukin-6 by peritoneal macrophages in vivo and in culture.

Authors:  G K Wollenberg; L E DeForge; G Bolgos; D G Remick
Journal:  Am J Pathol       Date:  1993-10       Impact factor: 4.307
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.